Philippe Camus, M.D.

Dijon, France

Both apps are now back!

Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

L.t

Cavitation/necrosis of lung tumor or metastases

May then fill-in with time (PMID 22743083) or leave a residual cyst or cysts

Publications

McNierney D, Owda F, Salim HA, Mallah SMA, Azar J

Bevacizumab-induced pulmonary cystic disease.

Respirology case reports 2024 Mar;12;e01321 — 2024 Mar

Iida T, Yabana T, Nakagaki S, Adachi T, Kondo Y

A Rupture of a Lung Metastatic Lesion of Colon Cancer, Leading to Pneumothorax Caused by Bevacizumab.

Internal medicine (Tokyo, Japan) 2016;55;3125-3129 — 2016 — 3125-3129

Souza FF, Smith A, Araujo C, Jagannathan J, Johnston C, O'Regan K, Shinagare A, Ramaiya N

New targeted molecular therapies for cancer: radiological response in intrathoracic malignancies and cardiopulmonary toxicity: what the radiologist needs to know.

Cancer imaging : the official publication of the International Cancer Imaging Society 2014 Jul 23;14;26 — 2014 Jul 23 — 26

Nishino M, Cryer SK, Okajima Y, Sholl LM, Hatabu H, Rabin MS, Jackman DM, Johnson BE

Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab.

Cancer imaging : the official publication of the International Cancer Imaging Society 2012 Jun 29;12;225-35 — 2012 Jun 29 — 225-35